Breaking News Instant updates and real-time market news.

ALKS

Alkermes

$34.80

0.6 (1.75%)

07:14
04/25/19
04/25
07:14
04/25/19
07:14

Alkermes backs FY19 EPS view 25c-43c, consensus 36c

Still sees FY19 revenue $1.14B-$1.19B, consensus $1.16B.

  • 25

    Apr

ALKS Alkermes
$34.80

0.6 (1.75%)

04/12/19
GSCO
04/12/19
NO CHANGE
Target $27
GSCO
Sell
Goldman still thinks ALKS 3831 is 'unlikely to be practice changing'
After Alkermes presented additional details on efficacy and safety, as well as the first look at the metabolic data from the Enlighten-2 trial and interim data from the ongoing extension study, Goldman Sachs analyst Terence Flynn continues to believe the company's schizophrenia drug ALKS 3831 is "unlikely to be practice changing." The analyst reiterates a Sell rating on the shares with a $27 price target. ALKS 3831 demonstrated a comparable metabolic profile relative to Zyprexa over the 24-week portion of the trial, Flynn tells investors in a research note. The analyst believes an outstanding question remains with respect to potential long term type 2 diabetes risk. It is unclear if the existing ALKS 3831 data will be enough to drive a differentiated label for the drug versus Zyprexa in this regard, which could have commercial implications, says the analyst.
04/12/19
PIPR
04/12/19
NO CHANGE
Target $32
PIPR
Neutral
Alkermes' ALKS-3831 ph3 data saw negligible relative benefit, says Piper Jaffray
Piper Jaffray analyst Danielle Brill kept her Neutral rating and $32 price target on Alkermes after its Phase 3 schizophrenia trial data for ALKS-3831 presented at SIRS conference. The analyst says the results showed some "beneficial impacts on weight gain with '3831" when patients switched from olanzapine, but the benefit on metabolic parameters was negligible. Brill states that Alkermes management intends to file a new drug application for '3831 by mid-2019, and while she believes the data support approval, she questions the program's "overall commercial opportunity" relative to other available agents with "more benign safety profiles."
04/15/19
JEFF
04/15/19
NO CHANGE
Target $36
JEFF
Hold
ALKS 3831 could see initial use in olanzapine patients, says Jefferies
Jefferies analyst Biren Amin says the key opinion leaders he spoke to indicate ALKS 3831 could see initial use and uptake in patents already on olanzapine but that the drug's use will be limited. Key opinion leaders found the absolute four pound decrease at six months between the two treatment groups to be lacking, with a desire for a minimum of 10 pounds or greater in average weight decrease in patients that were on 3831 versus olanzapine, Amin tells investors in a research note. Further, regarding the drug's metabolic profile, since no change in lipid or glucose profile was observed and given that the study wasn't powered to detect a difference between treatment arms, the data was not considered meaningful by most opinion leaders, adds the analyst. His base case puts ALKS 3831 peak sales at $500M. Amin keeps a Hold rating on Alkermes with a $36 price target.
04/18/19
JPMS
04/18/19
NO CHANGE
Target $41
JPMS
Overweight
Alkermes shares trading near base business value, says JPMorgan
Ahead of his conference call today with CEO Richard Pops, JPMorgan analyst Cory Kasimov says shares of Alkermes are trading near the company's base business value of $33 and that fundamental downside risk at these levels is "relatively limited." What is harder to determine is whether Alkermes shares will remain range bound for a prolonged period of time or if the company will start to get credit for its later stage product candidates, Kasimov tells investors in a research note. The analyst believes ALKS 3831 and Vumerity are "worth something at this juncture" and that improving investor sentiment will be key, along with solid execution in the near term, to unlock this potential value. He maintains an Overweight rating on Alkermes with a $41 price target.

TODAY'S FREE FLY STORIES

AKRO

Akero Therapeutics

$0.00

(0.00%)

11:32
06/20/19
06/20
11:32
06/20/19
11:32
Syndicate
Breaking Syndicate news story on Akero Therapeutics »

Akero Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

TYPE

Monotype Imaging

$17.90

1.41 (8.55%)

11:30
06/20/19
06/20
11:30
06/20/19
11:30
Recommendations
Monotype Imaging analyst commentary  »

Private equity buyer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EMLC

VanEck Vectors J.P. Morgan EM Local Currency Bond ETF

$34.54

0.27 (0.79%)

11:30
06/20/19
06/20
11:30
06/20/19
11:30
Options
Upside call buyer in thinly traded Emerging Markets Sovereign Debt ETF »

Upside call buyer in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WORK

Slack Technologies

$0.00

(0.00%)

11:29
06/20/19
06/20
11:29
06/20/19
11:29
Syndicate
Breaking Syndicate news story on Slack Technologies »

Slack Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKRO

Akero Therapeutics

$0.00

(0.00%)

11:28
06/20/19
06/20
11:28
06/20/19
11:28
Syndicate
Akero Therapeutics indicated to open at $16.76, IPO priced at $16.00 »

Akero Therapeutics (AKRO)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

11:25
06/20/19
06/20
11:25
06/20/19
11:25
General news
Oil Action: WTI crude advanced as much as 6% »

Oil Action: WTI crude…

QGEN

Qiagen

$41.02

0.34 (0.84%)

11:25
06/20/19
06/20
11:25
06/20/19
11:25
Conference/Events
Qiagen to host analyst & investor day »

Analyst & Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 06

    Aug

AIR

AAR Corp.

$33.83

0.125 (0.37%)

11:23
06/20/19
06/20
11:23
06/20/19
11:23
Hot Stocks
AAR, Tawazun Economic Council and GAL sign joint repair management deal »

AAR announced a new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

GO

Grocery Outlet

$0.00

(0.00%)

11:22
06/20/19
06/20
11:22
06/20/19
11:22
Syndicate
Breaking Syndicate news story on Grocery Outlet »

Grocery Outlet indicated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

WORK

Slack Technologies

$0.00

(0.00%)

11:20
06/20/19
06/20
11:20
06/20/19
11:20
Syndicate
Breaking Syndicate news story on Slack Technologies »

Slack Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GNLN

Greenlane

$12.23

1.25 (11.38%)

11:19
06/20/19
06/20
11:19
06/20/19
11:19
Recommendations
Greenlane analyst commentary  »

Greenlane fundamentals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CCL

Carnival

$47.60

-5.25 (-9.93%)

11:18
06/20/19
06/20
11:18
06/20/19
11:18
Downgrade
Carnival rating change  »

Carnival downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

CTST

CannTrust

$5.31

-0.05 (-0.93%)

, CURR

CURE Pharmaceutical

$0.00

(0.00%)

11:17
06/20/19
06/20
11:17
06/20/19
11:17
On The Fly
Rising High: CannTrust launches U.S. operations with California JV »

In this week's "Rising…

CTST

CannTrust

$5.31

-0.05 (-0.93%)

CURR

CURE Pharmaceutical

$0.00

(0.00%)

CGC

Canopy Growth

$43.05

0.275 (0.64%)

ACRGF

Acreage Holdings

$0.00

(0.00%)

TLRY

Tilray

$47.00

1.55 (3.41%)

IIPR

Innovative Industrial Properties

$135.35

10.335 (8.27%)

ORTFD

Biome Grow

$0.00

(0.00%)

APHA

Aphria

$6.75

0.01 (0.15%)

ACB

Aurora Cannabis

$7.46

-0.025 (-0.33%)

MMNFF

MedMen

$0.00

(0.00%)

ORHOF

Origin House

$0.00

(0.00%)

KSHB

KushCo Holdings

$0.00

(0.00%)

CRON

Cronos Group

$16.50

0.655 (4.14%)

MLCPF

MediPharm Labs

$0.00

(0.00%)

CVSI

CV Sciences

$0.00

(0.00%)

CANN

General Cannabis

$0.00

(0.00%)

IGC

India Globalization Capital

$1.32

0.09 (7.32%)

KNHBF

ICC International Cannabis

$0.00

(0.00%)

NDVAF

INDIVA

$0.00

(0.00%)

OGRMF

Organigram

$0.00

(0.00%)

ELLXF

Elixinol Global

$0.00

(0.00%)

PLNHF

Planet 13 Holdings

$0.00

(0.00%)

MRRCF

Wayland Group

$0.00

(0.00%)

KHRNF

Khiron Life Sciences

$0.00

(0.00%)

LHSIF

Liberty Health Sciences

$0.00

(0.00%)

SNNVF

Sunniva

$0.00

(0.00%)

HMDEF

DionyMed Brands

$0.00

(0.00%)

SRUTF

Sproutly

$0.00

(0.00%)

GRWG

Grow Generation

$0.00

(0.00%)

HRVSF

Harvest Health & Recreation

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 21

    Jun

  • 25

    Jun

  • 26

    Jun

  • 27

    Jun

  • 28

    Jun

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

11:17
06/20/19
06/20
11:17
06/20/19
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

11:16
06/20/19
06/20
11:16
06/20/19
11:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KKR

KKR

$24.52

0.23 (0.95%)

11:15
06/20/19
06/20
11:15
06/20/19
11:15
Options
KKR put volume heavy and directionally bearish »

Bearish flow noted in KKR…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:15
06/20/19
06/20
11:15
06/20/19
11:15
General news
Treasury announced a $113 B in coupon sales for next week »

Treasury announced a $113…

11:15
06/20/19
06/20
11:15
06/20/19
11:15
General news
Breaking General news story  »

4-Week Bill Auction to be…

11:15
06/20/19
06/20
11:15
06/20/19
11:15
General news
Breaking General news story  »

8-Week Bill Auction to be…

BGNE

BeiGene

$124.98

4.98 (4.15%)

11:09
06/20/19
06/20
11:09
06/20/19
11:09
Hot Stocks
BeiGene announces Phase 1b results of zanubrutinib with Gazyva »

BeiGene announced results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

PSNL

Personalis

$0.00

(0.00%)

11:09
06/20/19
06/20
11:09
06/20/19
11:09
Syndicate
Breaking Syndicate news story on Personalis »

Personalis indicated to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

AMRN

Amarin

$19.82

0.4 (2.06%)

11:08
06/20/19
06/20
11:08
06/20/19
11:08
On The Fly
Jefferies sees Amarin stock poised for even more gains »

Seeing the stock's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

STLD

Steel Dynamics

$29.25

-0.45 (-1.52%)

11:05
06/20/19
06/20
11:05
06/20/19
11:05
Options
Steel Dynamics call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSON

Misonix

$23.52

(0.00%)

11:04
06/20/19
06/20
11:04
06/20/19
11:04
Hot Stocks
Breaking Hot Stocks news story on Misonix »

Misonix up 39c to $24.17…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MLNT

Melinta Therapeutics

$5.28

-1.02 (-16.19%)

11:04
06/20/19
06/20
11:04
06/20/19
11:04
Recommendations
Melinta Therapeutics analyst commentary  »

Gabelli fears Melinta…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.